Fixed‑Dose Combination Therapy for Hypertension: Evidence‑Based Recommendations

Guideline‑Supported Recommendations

The American College of Cardiology/American Heart Association (ACC/AHA) classifies single‑pill antihypertensive combinations as Class I, Level B‑R recommendations to improve medication adherence in adults with hypertension【1】.
The ACC/AHA also rates once‑daily dosing (versus multiple daily doses) as Class I, Level B‑R for enhancing adherence【1】.
The 2024 European Society of Cardiology (ESC) guidelines state that fixed‑dose single‑pill combinations are recommended for patients already receiving combination blood‑pressure‑lowering therapy【2】.

A systolic/diastolic reading of 147/83 mm Hg meets criteria for uncontrolled Stage 2 hypertension (systolic ≥ 140 mm Hg)【1】.
The patient’s regimen of an angiotensin‑II receptor blocker (ARB) + calcium‑channel blocker (CCB) + thiazide diuretic aligns with guideline‑endorsed three‑drug combinations for individuals who require three antihypertensive agents【2】.

Up to 50 % of patients discontinue or inconsistently take antihypertensive medications within one year, making non‑adherence a major contributor to inadequate blood‑pressure control【1】.
Switching to a fixed‑dose combination (FDC) pill is recommended to improve adherence and achieve better blood‑pressure control in this context【1】【2】.

Clinicians should monitor for (orthostatic) hypotension, especially in older adults, when initiating or intensifying fixed‑dose antihypertensive therapy【1】.
Concurrent use of two renin‑angiotensin‑system (RAS) blockers (e.g., ACE inhibitor + ARB or either with aliskiren) should be avoided because it raises the risk of hypotension, hyperkalaemia, and renal dysfunction【1】【2】.

Patients are advised to take the FDC at the most convenient time of day to create a consistent habit and further support adherence, as endorsed by ESC guidance【2】.